AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06716242 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood collection
Description: Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
Study NCT05833906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 4
Description: Subjects will be administered 10 g of CKR-051.
Study NCT05833906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.
Study NCT06716931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated.~In person exercise supervised by physical therapist and then self-directed exercise in Group A
Study NCT06716931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise virtually supervised by physical therapist and then self-directed for group B
Study NCT06716931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Self-directed and virtually supervised exercise by physical therapist for Group C
Study NCT06714708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
Study NCT06714708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
Study NCT06717880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 combined with Bevacizumab
Description: IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection.
Study NCT06717568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention
Description: This is a diagnostic test with no intervention.
Study NCT04414436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GYNEA- digital coping program for women after gynaecological cancer
Description: 6 modules with relevant information and tools for coping after cancer
Study NCT06206083 — intervention group
Intervention type: GENETIC
Intervention: Descriptive and analytical
Description: Patients with EC endometroid
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device-based feedback, self-monitoring, and education: CORE
Description: Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation.
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Device-based feedback, self-monitoring, and education: CORE
Description: Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation.
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Screen Time lockout: LOCKOUT
Description: Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Screen Time lockout: LOCKOUT
Description: Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Context-based prompts: TEXT
Description: The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context-based prompts: TEXT
Description: The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
Study NCT04464993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Earn sedentary screen time through moderate-vigorous physical activity: EARN
Description: Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a >5 min continuous bout of exercise (as defined by Fitbit minutes >4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
Study NCT06719102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAGIC-FEED
Description: Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.
Study NCT06719102 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MAGIC-SAFE
Description: Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
Study NCT04641390 — intervention group
Intervention type: OTHER
Intervention: Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment
Description: The analysis of the seminal microbiome will be carried out by massive genetic sequencing
Study NCT04641390 — intervention group
Intervention type: OTHER
Intervention: Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment
Description: The analysis of the seminal microbiome will be carried out by massive genetic sequencing
Study NCT04755465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics.
Study NCT04755465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Description: Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
Study NCT05087459 — intervention group
Intervention type: DRUG
Intervention: Avatrombopag
Description: On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
Study NCT05163977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
Study NCT05163977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cattell Warren Anastomosis
Description: It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
Study NCT04540302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit WRAPSODY Endovascular Stent Graft
Description: Target lesion treated with stent graft placement
Study NCT04540302 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PTA
Description: Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
Study NCT06714903 — intervention group
Intervention type: OTHER
Intervention: treatment option-sintilimab plus fruquintinib
Description: sintilimab plus fruquintinib
Study NCT05405595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG126
Description: ADG126 and Pembrolizumab (KEYTRUDA®) combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
Study NCT06714903 — intervention group
Intervention type: OTHER
Intervention: treatment option-fruquintinib alone
Description: fruquintinib alone
Study NCT06719271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants this group will receive gait training in robotic assisted gait training (RAGT) three times per week for eight weeks
Description: Robotic Assited Gait Training is a device used to train children with CP how to walk in effective manner by connecting their body to the harness, robotic devices that attached to the electronic treadmill
Study NCT06719271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: Participants in this group will receive gait training on conventional treadmill three times per week for eight weeks
Study NCT06719297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive-sensorimotor VR/MR training
Description: Thinking task integrated walking and balance training program
Study NCT06719297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard walking and balance training
Study NCT06717191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biosimilar insulin glargine
Description: Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
Study NCT06715189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum Adiponectine and Resistin
Description: corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
Study NCT06715189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fibroscan
Description: hepatic fibrosis detection in type 2 diabetes mellutis
Study NCT06717737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group： Maintaining old exercise habits
Description: The control group will maintain their original daily habits without any intervention behaviors for them
Study NCT06717737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group：Conducted a 6-month team training intervention
Description: Spanning six months, the program incorporated aerobic training, resistance training, and functional exercises essential for rescue operations. Each training session was led by certified professionals who emphasized adherence to safety protocols and provided real-time feedback.~Central to the training process was the significance of teamwork and mutual support, with sessions conducted in small groups focused on shared objectives. This framework fostered a collaborative environment that promoted peer support and motivated participants to actively engage in their fitness regimen. The group setting enabled firefighters to encourage one another and share individual progress, thereby enhancing their sense of responsibility and belonging.
Study NCT06715085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
Study NCT06715085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.
Description: The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
Study NCT06719115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UClear
Description: Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
Study NCT06719115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
Study NCT06715826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
Study NCT06715826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-T4
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
Study NCT06715826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-H2D3
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
Study NCT06715826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RB14
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Study NCT06048926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: 200 mg/time, iv, Q3W
Study NCT06048926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel injection
Description: 50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
Study NCT06048926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: 50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
Study NCT06048926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
Study NCT06048926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
Study NCT06048926 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
Study NCT06048926 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
Study NCT06715969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Techniques
Description: Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.
Study NCT06715969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Induction Techniques
Description: MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)
Study NCT06715969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classıcal phsyotherapy
Description: 15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
Study NCT06719518 — intervention group
Intervention type: DEVICE
Intervention: ViTrack device
Description: In the operating room the ViTrack™ device will be applied the wrist. Monitoring will start in the operating room and will continue throughout the surgery. The device can be worn on either wrist. It will be connected to a power unit that will capture blood pressure data and stream the data to a secure laptop
Study NCT06717815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG11406
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Study NCT06716203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5 mg BGM0504 Administered SC
Description: Drug: BGM0504 Administered SC
Study NCT06716203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: : 10 mg BGM0504 Administered SC
Description: Drug: BGM0504 Administered SC